Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Nine patients die in phase II ELND 005 trial

    This is a preview of subscription content, log in to check access.


    1. 1.

      Elan Corporation plc, Transition Therapeutics Inc.Elan and Transition Therapeutics Announce Modifications to ELND005 Phase II Clinical Trials in Alzheimer's Disease. Media Release: 15 Dec 2009. Available from: URL:

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Nine patients die in phase II ELND 005 trial. React. Wkly. 1283, 3 (2010).

    Download citation


    • Public Health
    • Adverse Event
    • Placebo
    • Extension Study
    • Dose Group